Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: After poliomyelitis has been eradicated, access to live polioviruses will be highly restricted and the use of oral poliovirus vaccine (OPV) will probably be discontinued. Countries using OPV must decide whether to switch to inactivated poliovirus vaccine (IPV) or stop polio vaccination. Because data on the immunogenicity of IPV in tropical developing countries are limited, we conducted a randomized, controlled trial of IPV in Cuba. METHODS: The study population consisted of healthy infants born in Havana. A total of 166 infants were randomly assigned to two groups. Group A received a combination of the diphtheria-pertussis-tetanus (DPT) vaccine, the Haemophilus influenzae type b (Hib) vaccine, and IPV (DPT-Hib-IPV) at 6, 10, and 14 weeks of age. Group B, the control group, received a combination of the DPT vaccine and the Hib vaccine at 6, 10, and 14 weeks of age. Another group (group C, 100 infants), which did not undergo randomization at the same time as groups A and B, received the DPT-Hib-IPV combination at 8 and 16 weeks of age. Serum samples were collected before vaccination and at least 4 weeks after the last dose. Stool samples were obtained before and 7 days after challenge with OPV. RESULTS: The seroconversion rates in group A were 94%, 83%, and 100% for types 1, 2, and 3 poliovirus, respectively. There were no seroconversions in group B. The seroconversion rates in group C were 90%, 89%, and 90% for poliovirus types 1, 2, and 3, respectively. For groups A, B, and C, the virus isolation rates after challenge with OPV were 94%, 91%, and 97%, respectively, and the mean log10 viral titers of any serotype were 3.46, 3.89, and 3.37, respectively. There was one major adverse event, an episode of hypotonia. CONCLUSIONS: Vaccination with two or three doses of IPV resulted in a rate of seroconversion of at least 90%, except for seroconversion against type 2. The viral titer of OPV shed in the stool after OPV challenge was reduced in both groups receiving IPV. (ClinicalTrials.gov number, NCT00260312 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have shown that IPV reduces the duration and rate of virus shedding in immunised individuals compared with unimmunised individuals, although IPV is not effective in preventing PV replication in the gut [69,70].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [69]
Citations
Cites
Kew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., et al. (2002) · Science · doi:10.1126/science.1068284 · Cited by 600
Cody, C. L., Baraff, L. J., Cherry, J. D., Marcy, S. M., & Manclark, C. R. (1981) · Pediatrics · doi:10.1542/peds.68.5.650 · Cited by 536
Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993
Yang, C.-F., Naguib, T., Yang, S.-J., Nasr, E., Jorba, J., Ahmed, N., Campagnoli, R., van der Avoort, H., Shimizu, H., Yoneyama, T., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.15.8366-8377.2003 · Cited by 233
Circulation of type 1 vaccine-derived poliovirus in the philippines in 2001
Shimizu, H., Thorley, B., Paladin, F. J., Brussen, K. A., Stambos, V., Yuen, L., Utama, A., Tano, Y., Arita, M., Yoshida, H., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.24.13512-13521.2004 · Cited by 146
Recombinant Vaccine–Derived Poliovirus in Madagascar
Rousset, D., Rakoto-Andrianarivelo, M., Razafindratsimandresy, R., Randriamanalina, B., Guillot, S., Balanant, J., Mauclère, P., & Delpeyroux, F. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0907.020692 · Cited by 138
Inactivated poliovirus vaccine: Past and present experience
Murdin, A. D., Barreto, L., & Plotkin, S. (1996) · Vaccine · doi:10.1016/0264-410x(95)00211-i · Cited by 135
Efficacy of inactivated poliovirus vaccine in India.
Krishnan, R., Jadhav, M., & John, T. J. (1983) · Europe PMC (PubMed Central) · Cited by 122
Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba
Lago, P. M., Gary, H. E., Pérez, L. S., Cáceres, V., Olivera, J. B., Puentes, R. P., Corredor, M. B., Jímenez, P., Pallansch, M. A., & Cruz, R. G. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg185 · Cited by 117
Henry, J. L., Jaikaran, E. S., Davies, J. R., Tomlinson, A. J. H., Mason, P. J., Barnes, J. M., & Beale, A. J. (1966) · Journal of Hygiene · doi:10.1017/s0022172400040389 · Cited by 101
Trial of a Supplemental Dose of Four Poliovirus Vaccines
Sutter, R. W., Suleiman, A. J. M., Malankar, P., Al-Khusaiby, S., Mehta, F., Clements, G. B., Pallansch, M. A., & Robertson, S. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009143431103 · Cited by 84
Research works printed but not linked: 11
- 2004, Wkly Epidemiol Rec, 79, 349
- 2004, Wkly Epidemiol Rec, 79, 401
- Sutter RW, 2004, Bull World Health Organ, 82, 31
- 2003, Wkly Epidemiol Rec, 78, 241
- 1996, Bull World Health Organ, 74, 253
- Mas Lago P, 1999, Bull World Health Organ, 77, 681
- Kok PW, 1992, Bull World Health Organ, 70, 93
- Krishnan R, 1983, Bull World Health Organ, 61, 689
- Simoes EA, 1985, Am J Dis Child, 139, 977
- Ghendon YUZ, 1961, Acta Virol, 5, 265
- Marine WM, 1962, Am J Hyg, 76, 173
Cited by
Hird, T. R., & Grassly, N. C. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002599 · Cited by 221
Austin, P. C., Manca, A., Zwarenstein, M., Juurlink, D. N., & Stanbrook, M. B. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.002 · Cited by 159
Resik, S., Tejeda, A., Lago, P. M., Diaz, M., Carmenates, A., Sarmiento, L., Alemañi, N., Galindo, B., Burton, A., Friede, M., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/651611 · Cited by 146
“In contrast to other trials, we can rule out the following potential causes for the low immunogenicity: (1) variation in intradermal administration, because all doses were administered in a standardized approach using a needle-free device; (2) low immunogenicity of IPV [46], because the seroconversion rates after intr…”
BackgroundResultEfficacy of inactivated poliovirus vaccine in India
Jafari, H., Deshpande, J. M., Sutter, R. W., Bahl, S., Verma, H., Ahmad, M., Kunwar, A., Vishwakarma, R., Agarwal, A., Jain, S., et al. (2014) · Science · doi:10.1126/science.1255006 · Cited by 112
Expert Review on Poliovirus Immunity and Transmission
Duintjer Tebbens, R. J., Pallansch, M. A., Chumakov, K. M., Halsey, N. A., Hovi, T., Minor, P. D., Modlin, J. F., Patriarca, P. A., Sutter, R. W., Wright, P. F., et al. (2013) · Risk Analysis · doi:10.1111/j.1539-6924.2012.01864.x · Cited by 109
Metadata
- Authors
- The Cuba IPV Study Collaborative Group
- Corresponding author
- The Cuba IPV Study Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-12
- Volume
- 356
- Issue
- 15
- Pages
- 1536-1544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2335890187
- Cited by
- 90
- References
- 22
- Citations by year
- 2024: 1 · 2023: 7 · 2021: 1 · 2020: 2 · 2019: 5 · 2018: 8 · 2017: 7 · 2016: 3 · 2015: 11 · 2014: 4 · 2013: 7 · 2012: 9
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- inactivated poliovirus vaccine, infants, poliovirus type 2, Cuba, tropical developing countries, vaccine adverse events, hypotonia, viral shedding in stool, polio eradication
- MeSH terms
- Antibodies, Viral, Cuba, Feces, Humans, Infant, Infant, Newborn, Poliomyelitis, Poliovirus Vaccine, Inactivated, Polysaccharides, Bacterial, Diphtheria-Tetanus-Pertussis Vaccine, Bacterial Capsules, Vaccines, Combined, Poliovirus, Haemophilus Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba. https://app.cochat.ai/papers/10.1056/nejmoa054960
- The paper
- The Cuba IPV Study Collaborative Group. (2007). Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba. New England Journal of Medicine. https://doi.org/10.1056/nejmoa054960
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.